

ISSUE @ A GLANCE

Atrial fibrillation and stroke: anticoagulation in trials and real-world settings
T.F. Lüscher 2915

CardioPulse

From basic science to high performance medicine
T. Eschenhagen 2919

From Bench to Bedside 2922

The German Cardiac Society
J.D. Schipke and G. Arnold 2923

Building a Bridge between Physicians and Patients
M. Wichert 2927


ZORA
S. Keller 2931

CLINICAL REVIEW

Clinical update
Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe
A.C. Fanaroff, J. Steffel, J.H. Alexander, G.Y.H. Lip, R.M. Califf, and R.D. Lopes 2932

FAST TRACK CLINICAL RESEARCH

Arrhythmia/electrophysiology



Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation

P. Kirchhof, K.G. Haeusler, B. Blank, J. De Bono, D. Callans, A. Elvan, T. Fetsch, I.C. Van Gelder, P. Gentlesk, M. Grimaldi, J. Hansen, G. Hindricks, H.R. Al-Khalidi, T. Massaro, L. Mont, J.C. Nielsen, G. Nölker, J.P. Piccini, T. De Potter, D. Scherr, U. Schotten, S. Themistoclakis, D. Todd, J. Vijgen, and L. Di Biase

2942

Editorial

Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?
D.J. Friedman and C.B. Granger 2956

Atrial fibrillation

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
M.D. Ezekowitz, C.V. Pollack Jr, J.L. Halperin, R.D. England, S. VanPelt Nguyen, J. Spahr, M. Sudworth, N.B. Cater, A. Breazna, J. Oldgren, and P. Kirchhof 2959

Editorial

Initiating anticoagulation with the intention of cardioverting: does drug choice matter?
K.W. Mahaffey and M.P. Turakhia 2972

CLINICAL RESEARCH

Atrial fibrillation

A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation

J.C. Cowan, J. Wu, M. Hall, A. Orlowski, R.M. West, and C.P. Gale


2975

Editorial

Major progress in anticoagulant uptake for atrial fibrillation at last: does it translate into stroke prevention?

B. Freedman

2984



Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial

M. Rienstra, A.H. Hobbelt, M. Alings, J.G.P. Tijssen, M.D. Smit, J. Brügemann, B. Geelhoed, R.G. Tieleman, H.L. Hillege, R. Tukkie, D.J. Van Veldhuisen, H.J.G.M. Crijns, and I.C. Van Gelder; for the RACE 3 Investigators

2987

Editorial

The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy

D. Pavlovic, P. Kirchhof, and L. Fabritz

2997

CARDIOVASCULAR FLASHLIGHTS

Pedunculated aortic thrombus propagating from the right coronary artery in a patient with IgA nephropathy

J. Scherman, N. da Silva, A. Myburgh, and T. Pennel

3000

A rare cause of pericardial effusion due to intracardiac cement embolism

P. Swojanowsky, M. Brinkmeier-Theofanopoulou, C. Schmitt, and U. Mehlhorn


3001



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site

<https://academic.oup.com/eurheartj>



www.eurheartj.org